EMA - European Medicines Agency · March 30, 2023

Warning about sharp rise in illegal medicines sold in the EU

EMA warns of serious health risks from illegal GLP-1 receptor agonist medicines marketed for weight loss and diabetes in the EU.

High impact Pharmaceuticals Public Health EU-wide falsified-medicinespharmacovigilance

Illegal medicines marketed as GLP-1 receptor agonists for weight loss and diabetes pose serious risk to health

Read the official source ↗

Published by EMA - European Medicines Agency. HealthSignal links to the original document; the summary above is extracted from the source text.